Description
Semax is a synthetic peptide analog of the ACTH (4–10) fragment, modified to increase stability and enhance its neurotropic activity. It has been extensively studied in neuropharmacological research for its nootropic, neuroprotective, and anti-inflammatory properties, particularly in models of cerebral ischemia, cognitive impairment, and neurodegenerative conditions.
Semax is believed to work through modulation of the brain-derived neurotrophic factor (BDNF) and dopaminergic and serotonergic pathways, contributing to improved synaptic plasticity, memory formation, and stress resilience. It has also been shown to influence gene expression related to neuroprotection and repair, and to enhance oxidative stress resistance at the cellular level.
In preclinical and clinical research, Semax is often investigated for its role in supporting cognitive recovery after brain injury, optimizing learning performance, and modulating the hypothalamic-pituitary-adrenal (HPA) axis during stress responses. Its non-stimulant profile and minimal systemic side effects make it an attractive candidate for neurological research.
There are no reviews yet.